Portfolio

Extensive vascular portfolio

Choose a partner that covers the procedures you perform today and the ones you’re planning for the future in your office-based lab (OBL) or ambulatory surgery center (ASC).

You’ll gain access to one of the largest portfolios of products in medical technology when you partner with us. We offer a comprehensive suite of products and therapies to treat varying degrees of vascular disease to help your patients get back to enjoying what they love.

Peripheral embolization
Deep venous
Superficial venous
Carotid
Arteriovenous access
Iliac, superficial femoral (SFA), and popliteal arteries
Below the knee (BTK)

About 80% of peripheral vascular interventions today have been reported to be catheter-based and can be performed in an OBL.¹ Our extensive selection of vascular products includes:

Product spotlight

TurboHawk™ Plus directional atherectomy system

Treat above and below the knee with the TurboHawk™ Plus directional atherectomy system to restore blood flow by removing plaque in patients with peripheral arterial disease.

Indications, Safety, and WarningsNote: Safety information provided is for the United States. Refer to your region’s instructions for use for specific details.This therapy is not for everyone. Please consult your physician. A prescription is required. Prior to use, refer to the instructions for use supplied with these devices for indications, contraindications, side effects, suggested procedure, warnings, and precautions. Important informationIndications, contraindications, warnings, and instructions for use can be found in the product labeling supplied with each device.Indications for use The TurboHawk™ peripheral plaque excision system is intended for use in the atherectomy of the peripheral vasculature. The TurboHawk™ catheter is not intended for use in the coronary, carotid, iliac, or renal vasculature.The TurboHawk™ catheter is indicated for use in conjunction with the SpiderFX™ embolic protection device in the treatment of severely calcified lesions (LX-C only).Caution: Federal law (United States) restricts this product for sale by or on the order of a physician.FTSOP113326-66 Rev. 1C

View brochure (open in new window)

VenaSeal™ closure system

Reach new lengths and treat more diseased veins with VenaSeal™ closure system. Deliver immediate and lasting vein closure with our proprietary medical adhesive^2–6 and provide patients with a rapid, same-day recovery.

Indications, Safety, and WarningsIntended use/indicationsThe VenaSeal™ closure system (VenaSeal™ system) is indicated for use in the permanent closure of lower extremity superficial truncal veins, such as the great saphenous vein (GSV), through endovascular embolization with coaptation. The VenaSeal™ system is intended for use in adults with clinically symptomatic venous reflux as diagnosed by duplex ultrasound (DUS).ContraindicationsSeparate use of the individual components of the VenaSeal™ closure system is contraindicated. These components must be used as a system. The use of the VenaSeal™ system is contraindicated when any of the following conditions exist: previous hypersensitivity reactions to the VenaSeal™ adhesive or cyanoacrylates, acute superficial thrombophlebitis, thrombophlebitis migrans, acute sepsis.Potential adverse effects of the device on healthThe potential adverse effects (e.g., complications) associated with the use of the VenaSeal™ system include, but are not limited to, adverse reactions to a foreign body (including, but not limited to, nonspecific mild inflammation of the cutaneous and subcutaneous tissue), arteriovenous fistula, bleeding from the access site, deep vein thrombosis (DVT), edema in the treated leg, embolization, including pulmonary embolism (PE), hematoma, hyperpigmentation, hypersensitivity or allergic reactions to cyanoacrylates, such as urticaria, shortness of breath, and anaphylactic shock, infection at the access site, pain, paresthesia, phlebitis, superficial thrombophlebitis, urticaria, erythema, or ulceration may occur at the injection site, vascular rupture and perforation, visible scarring.Instructions for use can be found in the product labeling at manuals.medtronic.com.Caution: Federal (United States) law restricts these devices to sale by or on the order of a physician.Important: Please reference the Instructions For Use (IFU) for a complete listing of indications, contraindications, warnings and precautions, adverse effects, and suggested procedure.

See how it works

Abre™ venous self-expanding stent system

The Abre™ stent system is designed for the unique challenges of venous disease. It offers easy deployment to let physicians focus on their patient and delivers demonstrated endurance to give patients freedom of movement.^7,8

Indications, Safety, and WarningsIndications for useThe Abre™ venous self-expanding stent system is intended for use in the iliofemoral veins for the treatment of symptomatic venous outflow obstruction.Cautions

This device was designed for single use only. Do not reuse, reprocess, or resterilize this device. Reuse, reprocessing, or resterilization may compromise the structural integrity of the device or create a risk of contamination, which could result in patient injury, illness, or death.

If unusually high resistance is encountered when advancing the Abre™ delivery system over the guidewire, assess the cause of the resistance before proceeding.

If high resistance is felt when initially rotating the thumbwheel, do not force deployment. Carefully withdraw the system and do not use it.

Do not use in patients with a total venous occlusion that cannot be dilated to allow passage of the guidewire.

Do not use the device with contralateral access.

Stenting across a major branch could cause difficulties during future diagnostic or therapeutic procedures.

Contraindications

Do not use the Abre™ system with patients with known hypersensitivity to nickel titanium (nitinol).

Do not use the Abre™ system with patients who are judged to have a lesion that prevents complete inflation of a balloon dilatation catheter or proper placement of the stent or the stent delivery system.

Do not use the Abre™ system with patients in whom anticoagulant or antiplatelet therapy is contraindicated.

Potential complicationsThe potential adverse events (or complications) that may occur or require intervention with the use of this device include, but are not limited to, the following:

Access failure

Access site infection

Allergic reaction to contrast medium or procedure medications

Allergic reaction to nitinol or other device materials

Aneurysm

AV fistula

Bleeding

Bruising

Death

Device breakage

Device maldeployment

Edema

Embolization

Fever

Hematoma

Hypertension

Hypotension, nausea, or other vasovagal response

Infection

Myocardial infarction, arrhythmia, or other cardiovascular insufficiency

Open surgical repair

Pain

Pseudoaneurysm

Renal insufficiency or renal failure (new or worsening)

Respiratory distress or pulmonary embolism

Sepsis

Stent fracture

Stent malapposition

Stent malposition

Stent migration

Stroke, paradoxical embolism, transient ischemic attack, or intracerebral hemorrhage

Tissue necrosis

Venous occlusion, restenosis, or thrombosis, within or outside of stented segment

Vessel damage, including intimal injury, dissection, perforation, or rupture

MRI safety informationMRI conditionalNonclinical testing demonstrated that the Abre™ stent in single and overlapped conditions is MR Conditional for stents up to 150 mm.A patient with this device can be scanned safely, immediately after stent placement, under the following conditions:

Static magnetic field of 1.5 Tesla or 3.0 Tesla

Maximum spatial gradient magnetic field of 4000 Gauss/cm or less (40 T/m)

Maximum MR system-reported, whole-body-averaged specific absorption rate (SAR) of 2.0 W/kg (normal operating mode)

MR image quality may be compromised if the area of interest is in the exact location or close to the position of the Abre™ stent.MRI-related temperature riseUnder the scan conditions as defined in the previous section, "MR Conditional," the Abre™ stent is expected to produce a maximum temperature rise less than or equal to 5.2 C after 15 minutes of continuous scanning (per pulse sequence). The effect of temperature rise in the MRI environment for stents with fractured struts is not known.It is recommended that patients register conditions under which the implant can be scanned safely with the MedicAlert Foundation (medicalert.org) or equivalent organization.Artifact informationIn nonclinical testing, the maximum artifact size as seen on the gradient echo pulse sequence at 3.0 Tesla extends approximately 5 mm, relative to the size and shape of the Abre™ stent. The lumen of the stent can be visualized using the T1-weighted spin echo pulse sequence and the T1-weighted gradient echo pulse sequence at 3.0 Tesla.

Explore the Abre™ system

ClosureFast™ radiofrequency ablation system

The ClosureFast™ procedure, now in 6 Fr, uses radiofrequency energy to treat patients with superficial vein disease.

Indications, Safety, and WarningsSuperficial vein productsQuick links to products

VenaSeal™ closure system

ClosureFast™ radiofrequency ablation (RFA) catheter

ClosureRFS™ radiofrequency stylet

Closure RFG™ radiofrequency generator

VenaSeal closure systemIntended use/indicationsThe VenaSeal closure system (VenaSeal system) is indicated for use in the permanent closure of lower extremity superficial truncal veins, such as the great saphenous vein (GSV), through endovascular embolization with coaptation. The VenaSeal system is intended for use in adults with clinically symptomatic venous reflux as diagnosed by duplex ultrasound (DUS).ContraindicationsSeparate use of the individual components of the VenaSeal closure system is contraindicated. These components must be used as a system. The use of the VenaSeal system is contraindicated when any of the following conditions exist: previous hypersensitivity reactions to the VenaSeal™ adhesive or cyanoacrylates, acute superficial thrombophlebitis, thrombophlebitis migrans, acute sepsis.Potential adverse effects of the device on healthThe potential adverse effects (e.g., complications) associated with the use of the VenaSeal system include, but are not limited to, adverse reactions to a foreign body (including, but not limited to, nonspecific mild inflammation of the cutaneous and subcutaneous tissue), arteriovenous fistula, bleeding from the access site, deep vein thrombosis (DVT), edema in the treated leg, embolization, including pulmonary embolism (PE), hematoma, hyperpigmentation, hypersensitivity or allergic reactions to cyanoacrylates, such as urticaria, shortness of breath, and anaphylactic shock, infection at the access site, pain, paresthesia, phlebitis, superficial thrombophlebitis, urticaria, erythema, or ulceration may occur at the injection site, vascular rupture and perforation, visible scarring.Instructions for use can be found in the product labeling at manuals.medtronic.com.Caution: Federal (United States) law restricts these devices to sale by or on the order of a physician.ClosureFast radiofrequency ablation (RFA) catheter
Intended use/indicationsThe ClosureFast™ radiofrequency ablation (RFA) catheter is intended for endovascular coagulation of blood vessels in patients with superficial vein reflux.ContraindicationsThe ClosureFast catheter is contraindicated for use in patients with thrombus in the target vein segment.Potential adverse effects of the device on healthThe potential complications include, but are not limited to, the following: adjacent nerve injury, hematoma, pulmonary embolism, thrombosis, infection, phlebitis, skin burn or discoloration, and vessel perforation.Important: Please reference the Instructions For Use (IFU) for a complete listing of indications, contraindications, warnings and precautions, adverse effects, and suggested procedure.Caution: Federal (United States) law restricts these devices to sale by or on the order of a physician.ClosureRFS radiofrequency stylet
Intended use/indicationsThe ClosureRFS™ stylet is intended for use in vessel and tissue coagulation, including treatment of incompetent (i.e., refluxing) perforator and tributary veins.ContraindicationsThe ClosureRFS stylet is contraindicated for use in patients with thrombus in the vein segment to be treated.Potential adverse effects of the device on healthThe potential complications include, but are not limited to, the following: arteriovenous fistula, infection, phlebitis, skin burns, hematoma, nerve damage, pulmonary embolism, and thrombosis.Important: Please reference the Instructions For Use (IFU) for a complete listing of indications, contraindications, warnings and precautions, adverse effects, and suggested procedure.Caution: Federal (United States) law restricts these devices to sale by or on the order of a physician.ClosureRFG radiofrequency generator
Indications for UseThe ClosureRFG generator is used with radiofrequency catheters intended for vessel and tissue coagulation.ContraindicationRefer to the applicable radiofrequency catheter instructions for use for a list of contraindications related to a ClosureFast system procedure.Potential adverse effects of the device on healthRefer to the applicable radiofrequency catheter instructions for use for a list of potential complications related to a ClosureFast system procedure.Important: Please reference to the Operation Manual for a complete listing of indications, warnings, precautions, safety notices, and operational information.Caution: Federal (United States) law restricts these devices to sale by or on the order of a physician.UC202411547EN

See ClosureFast™ technology

Concerto™ Helix detachable coil system

The Concerto™ coil system offer helical and complex options for peripheral embolization, in diameters from 2 to 20 mm.

Indications, Safety, and WarningsIndications (or Intended Use)The Concerto™ detachable coil system is indicated for arterial and venous embolizations in the peripheral vasculature.ContraindicationsThere are no known contraindications.Potential Adverse Events (or Potential Complications)The potential complications include, but are not limited to, the following: puncture site hematoma, thromboembolic episodes, vessel perforation, neurological deficits including stroke and death, vasospasms, vascular thrombosis, hemorrhage, and ischemia.CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device, at www.medtronic.com/manuals, or contact a Medtronic representative.FTSOP113326-42c
UC202113743-01a EN

Discover the Concerto™ system

Extensive vascular portfolio

Product spotlight

TurboHawk™ Plus directional atherectomy system

VenaSeal™ closure system

Abre™ venous self-expanding stent system

ClosureFast™ radiofrequency ablation system

Concerto™ Helix detachable coil system

United States

Customer Care Team